C.S.O
Yurogen Biosystems (an ABclonal Company)
Hao Cheng, Ph.D., chief scientific officer at Yurogen Biosystems and Abclonal Technology.
Dr. Hao Cheng currently holds the position of Chief Scientific Officer at Yurogen Biosystems, a subsidiary company of Abclonal Technology. Additionally, he serves as an Associate Professor at the School of Life Sciences, Southeast University, China. Before his role at Yurogen Biosystems, Dr. Cheng played a pivotal role in the R&D department at Entrada Therapeutics, where he spearheaded antibody discovery efforts aimed at the development of antibody-based PROTACs, ultimately leading to the degradation of cell surface receptors and intracellular targets.Prior to his tenure at Entrada, Dr. Cheng co-founded OcculoBio LLC, a biotechnology company renowned for its expertise in AI-assisted biological deimmunization. During his time at OcculoBio, he led the discovery and development of deimmunized biotherapeutic pipelines, culminating in the successful acquisition by a private pharmaceutical company.Dr. Cheng earned his Ph.D. in microbiology and immunology from Thayer Engineering School of Dartmouth College and holds a B.S. degree from the Life Science department at Wuhan University, China.